Sir,
Epilepsy affects 40 million people worldwide, threequarters of whom remain untreated. About 75% of the 40 million people with epilepsy worldover are in developing countries. However, with early diagnosis and treatment, epilepsy can be controlled in three-quarters of those affected 1 . Since the prevalence rate of active epilepsy in India is 5.5/1000, the number of active epilepsy patients in India will amount to 5.4 million, i.e. one-eighth of the total epilepsy patients in the world 2 .
A recent meta-analysis, conducted by Sreedharan and Murthy 3 , estimated that the number of people with epilepsy by the year 2001 will be 5.5 million and the number of new cases of epilepsy every year as approximately half a million. Since 74% of the Indian population live in rural areas, the number of rural epilepsy patients would be ∼ 4.1 million, out of which ∼ 3.0 million will not be getting any treatment for epilepsy! The above statistics clearly shows the enormous burden of epilepsy for a developing country, like India, where the Gross National Product (GNP) per capita income is only US$ 390 (US$ 1 = Indian Rupees 43.0), whereas, the GNP per capita for United Kingdom (UK) and the United States of America (USA) are US$ 20 710 and 28 740 respectively 4 . Hence, there is an emergent need for an appropriate choice of antiepileptic drug (AED) for each epilepsy syndrome. Moreover, the emphasis should be on the choice of inexpensive AEDs like phenobarbital (PB) and phenytoin (DPH) over carbamazepine (CBZ) wherever possible, starting as monotherapy, based on the International League Against Epilepsy (ILAE) classification 5 .
Intractable epilepsy is most often the result of missed opportunities for therapy 6 . Sub-optimal use of antiepileptic drugs, non-compliance, inappropriate selection of AEDs, wrong AED for a wrong diagnosis, polypharmacy etc. can result in escalation of cost and intractability.
Following the era of widespread polytherapy for the treatment of epilepsy, it is now uniformly accepted that most cases of newly diagnosed epilepsy in children or adults can be controlled with a single AED [7] [8] [9] [10] . Evidence has accumulated in the literature that the correct selection of drug in the appropriate dose remains the cornerstone of treatment of epilepsy, toxicity and cost being an important consideration in this decision 11 . The affordability of medical care is a significant factor in choice of AEDs not only in the developing nations, but also in developed countries where medical accountability prevails. The pursuit of efficiency in health-care demands priority to be given to those treatments which provide the best benefit per unit of cost 12 . The education of patients regarding the importance of compliance and periodic drug level estimations are also important in the management of epilepsy 13 . Polypharmacy and frequent use of comparatively expensive AEDs such as CBZ and valproate (VPA) have escalated the cost of treatment in developing countries such as India. In addition, less expensive drugs such as PB and DPH remain under-utilized in our country 14 .
In this context, it will be prudent to consider studies on the efficacy of various AEDs in patients with similar seizure semiology. The drug of choice for absence seizures, juvenile myoclonic epilepsy and other primary generalized epilepsies, is VPA 15 . In a randomized comparative monotherapy trial of PB, DPH, CBZ and VPA in newly diagnosed childhood epilepsy, De Silva et al. 16 concluded that the overall outcome with all four drugs was good. There was no significant difference in efficacy between the drugs for these seizure types. One hundred and sixty-seven children aged 3-16 years, who had at least two previously untreated generalized tonic-clonic (GTC) or partial seizures, with or without secondary generalization (P±GTC) were included in the study. Children with any other type of seizure (e.g. absence, myoclonic jerks and drop attacks) were excluded from this study. The overall frequency of unacceptable side-effects necessitating withdrawal of drug was 9%. This included 6 of the first 10 children assigned PB; no further children were allocated this drug. Of the remaining three drugs, DPH was more likely to be withdrawn (9%) than CBZ (4%) and VPA (4%). These authors concluded that the choice of first AED for such children will be influenced largely by toxicity and cost.
Mattson et al. 17 , in a comprehensive study, noted that all the four AEDs (viz. CBZ, PB, DPH and prim-idone), have equal efficacy in controlling secondarily generalized tonic-clonic seizures. Since DPH and CBZ shared similar rates of adverse effects, the choice between them will depend on the prolonged half life and lower cost of the former. In another randomized comparative monotherapy trial from UK, Heller et al. 18 concluded that overall outcome with the four drugs, viz. PB, DPH, CBZ or VPA, was good. No significant differences were found between the four drugs for measure of efficacy. These authors re-iterated that considerations of toxicity and costs influenced the choice of drug. In this study, the incidence of unacceptable side effects necessitating withdrawal was more often for PB (22%) followed by CBZ (11%), VPA (5%) and DPH was the lowest (3%).
In the United States, DPH continues to be the most commonly used AED (48%) 19 , whereas in India, DPH and CBZ are used in about 25% and 44% of patients, respectively. In India, an average patient treated with PB, DPH, CBZ or VPA as monotherapy would spend 4.4, 7.1, 16.8 and 29.5% of gross national product per inhabitant (GNP/Capita) respectively 14 .
Therefore, in a country like India where the burden of epilepsy is tremendous and the need for costcontainment is pressing, DPH appears to be a better choice over CBZ and VPA, which I believe, would also reinforce better compliance, in the majority of people with epilepsy with partial, with or without secondary generalized, seizures. Judicious selection and use of antiepileptic drugs aided by advances in clinical neurophysiological testing modalities including electroencephalography (EEG), digital/video EEG and newer modes of therapy with epilepsy surgery and vagal nerve stimulation will go a long way in enhancing success in managing patients with epilepsy in developing countries.
